These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6541487)

  • 21. Pharmacokinetics of verproside after intravenous and oral administration in rats.
    Park EJ; Lee HS; Oh SR; Lee HK; Lee HS
    Arch Pharm Res; 2009 Apr; 32(4):559-64. PubMed ID: 19407974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long term lorcainide therapy guided by electrophysiology studies.
    Somberg J; Butler B; Flowers D; Tepper D; Torres V
    Acta Cardiol; 1985; 40(6):621-36. PubMed ID: 3879419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics.
    Vu VT; Bai SA; Abramson FP
    J Pharmacol Exp Ther; 1983 Jan; 224(1):55-61. PubMed ID: 6848749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin.
    Fromm MF; Busse D; Kroemer HK; Eichelbaum M
    Hepatology; 1996 Oct; 24(4):796-801. PubMed ID: 8855178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability.
    Yang SH; Lee MG
    Int J Pharm; 2007 Mar; 332(1-2):17-23. PubMed ID: 17157458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haemodynamic reactions after intravenous injection of lorcainide hydrochloride in acute myocardial infarction.
    Shita A; Bernard R; Mostinckx R; Debacker M
    Eur J Cardiol; 1981; 12(5):237-42. PubMed ID: 7250167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical and clinical pharmacokinetics of pirmenol.
    Chang T
    Am J Cardiol; 1987 Jun; 59(16):15H-19H. PubMed ID: 2438922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioavailabilty and pharmacokinetics of four active alkaloids of traditional Chinese medicine Yanhuanglian in rats following intravenous and oral administration.
    Li HL; Zhang WD; Zhang C; Liu RH; Wang XW; Wang XL; Zhu JB; Chen CL
    J Pharm Biomed Anal; 2006 Jun; 41(4):1342-6. PubMed ID: 16644173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disopyramide phosphate: pharmacokinetic and pharmacologic relationships of a new antiarrhythmic agent.
    Ranney RE; Dean RR; Karim A; Radzialowski FM
    Arch Int Pharmacodyn Ther; 1971 May; 191(1):162-88. PubMed ID: 4104224
    [No Abstract]   [Full Text] [Related]  

  • 31. Excretion and metabolism of lorcainide in rats, dogs and man.
    Meuldermans W; Hurkmans R; Swysen E; Hendrickx J; Thijssen J; Lauwers W; Heykants J
    Eur J Drug Metab Pharmacokinet; 1983; 8(4):335-49. PubMed ID: 6673971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Eiriksson Ce; Brogden RN
    Drugs; 1984 Apr; 27(4):279-300. PubMed ID: 6373222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The pharmacokinetics and metabolism of bonnecor in rats].
    Klemm V; Morgenroth U; Starke F; Zeriatke W; Ioram U
    Farmakol Toksikol; 1990; 53(3):43-4. PubMed ID: 2387379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lorcainide. II. Plasma concentration-effect relationship.
    Meinertz T; Kasper W; Kersting F; Just H; Bechtold H; Jähnchen E
    Clin Pharmacol Ther; 1979 Aug; 26(2):196-204. PubMed ID: 455888
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
    Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
    Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
    Chan S; Edwards SR; Wyse BD; Smith MT
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [HPLC method for determination of lorcainide hydrochloride in human serum].
    Luo X; Zeng FD
    Yao Xue Xue Bao; 1995; 30(8):605-9. PubMed ID: 8571780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical pharmacology of propafenone].
    Ambrosioni E; Marchesini B
    G Ital Cardiol; 1984 Apr; 14(4):285-92. PubMed ID: 6735021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of pharmacokinetics, brain levels and protein binding of centpropazine in rats.
    Bhattaram VA; Paliwal JK; Gupta RC
    Biopharm Drug Dispos; 2004 Mar; 25(2):69-75. PubMed ID: 14872554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.